Oncoloxía médica
Servizo
Enrique
Aranda Aguilar
Publicacións nas que colabora con Enrique Aranda Aguilar (25)
2023
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
-
Ibero-American Consensus Review and Incorporation of New Biomarkers for Clinical Practice in Colorectal Cancer
Cancers, Vol. 15, Núm. 17
-
SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022)
Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2718-2731
2022
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 24, Núm. 6, pp. 1209-1214
2021
-
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839
-
Early clinical experience with trifluridine/tipiracil for refractory metastatic colorectal cancer: The ros study
Cancers, Vol. 13, Núm. 18
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
2020
2019
-
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Scientific Reports
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Scientific Reports, Vol. 9, Núm. 1
-
First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: A pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
BMC Cancer, Vol. 19, Núm. 1
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470
-
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Oncologist, Vol. 23, Núm. 11, pp. 1271-e128
2017
-
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review
Annals of Oncology, Vol. 28, Núm. 12, pp. 2943-2949
2015
-
First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours
European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380
-
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324